NCT04968938View on ClinicalTrials.gov

Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

midomafetamine

80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose

BEHAVIORAL

Therapy

Manualized therapy

Sponsors

Lead Sponsor

Lykos Therapeutics
All Listed Sponsors
lead

Lykos Therapeutics

INDUSTRY